Tesla (TSLA 323.99, -50.02, -13.37%) is now the worst-performing S&P 500 component after its Q2 report paired a sizable adjusted EPS miss with weaker margins, negative free cash flow, and a much more aggressive investment posture for 2026.
Investors are looking past a top-line beat as automotive gross margin excluding regulatory credits fell to 16.3% from 19.2% sequentially, operating margin compressed to just 1.4%, regulatory-credit revenue declined sharply, and energy gross margin dropped to 20.4% from 39.5%, while management framed 2026 as a “massive CapEx year” with spending expected to exceed $25 billion across Robotaxi, Optimus, semiconductor capacity, solar manufacturing, and AI compute.
Demand quality: TSLA said Q2 vehicle deliveries were a record for a second quarter, with sequential growth of 60% in the Americas, 27% in APAC, and 12% in EMEA, and it exited the quarter with its largest order backlog since 2023. However, lower realized vehicle pricing suggests stronger volume came at the expense of profitability.
FSD monetization: Nearly 1.5 mln customers now pay for FSD globally, with 55% upfront purchases and 45% subscriptions. Management also said about 55% of North American Q2 deliveries had FSD subscription enabled at delivery, underscoring growing software adoption.
Energy reset: Energy storage deployments rose to 13.5 GWh, up 53% sequentially, but the margin collapse matters more for sentiment because management now expects the business to normalize in the mid- to low-20% gross margin range longer term.
Cash and spending: Free cash flow turned negative as CapEx more than doubled sequentially, largely reflecting accelerated investment rather than collapsing operating cash flow. TSLA ended the quarter with a sizable cash position and said debt facilities could provide up to $30 bln of borrowing capacity to support its expanded buildout if needed.
Execution watch: TSLA reiterated aggressive autonomy and robotics ambitions, including expansion to seven U.S. Robotaxi markets, first-generation Optimus production lines being installed for 2026, and a future “Terafab” announcement, while acknowledging regulatory scrutiny, supply-chain bottlenecks, and the difficulty of scaling these programs.
In addition to Tesla’s sharp loss, the consumer discretionary sector (-4.8%) faces broad pressure across its oil-sensitive and rate-sensitive stocks as crude continues to climb